|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neoadjuvant treatment of esophageal cancer显示文摘The management of esophageal cancer has been evolving over the past 30 years. In the United States, multimodality treatment combining chemotherapy and radiotherapy (RT) prior to surgical resection has come to be accepted by many as the standard of care, although debate about its overall effect on survival still exists, and rightfully so. Despite recent improvements in detection and treatment, the overall survival of patients with esophageal cancer remains lower than most solid tumors, which highlights why further advances are so desperately needed. The aim of this article is to provide a complete review of the history of esophageal cancer treatment with the addition of chemotherapy, RT, and more recently, targeted agents to the surgical management of resectable disease. | Nicholas P Campbell Victoria M Villaflor | 2010 | World Journal of Gastroenterology2010，16，30： | 16 |
| 2 | Multidisciplinary approach for patients with esophageal cancer显示文摘Patients with esophageal cancer have a poor prognosis because they often have no symptoms until their disease is advanced. There are no screening recommendations for patients unless they have Barrett's esophagitis or a significant family history of this disease. Often, esophageal cancer is not diagnosed until patients present with dysphagia, odynophagia, anemia or weight loss. When symptoms occur, the stage is often stage Ⅲ or greater. Treatment of patients with very early stage disease is fairly straight forward using only local treatment with surgical resection or endoscopic mucosal resection. The treatment of patients who have locally advanced esophageal cancer is more complex and controversial. Despite multiple trials, treatment recommendations are still unclear due to conflicting data. Sadly, much of our data is difficult to interpret due to many of the trials done have included very heterogeneous groups of patients both histologically as well as anatomically. Additionally, studies have been underpowered or stopped early due to poor accrual. In the United States, concurrent chemoradiotherapy prior to surgical resection has been accepted by many as standard of care in the locally advanced patient. Patients who have metastatic disease are treated palliatively. The aim of this article is to describe the multidisciplinary approach used by an established team at a single high volume center for esophageal cancer, and to review the literature which guides our treatment recommendations. | Victoria M Villaflor Marco E Allaix Bruce Minsky Fernando A Herbella Marco G Patti | 2012 | World Journal of Gastroenterology2012，18，46： | 9 |
| 3 | Curcuminoids and resveratrol as anti-Alzheimer agents 显示文摘 | Villaflores OB Chen YJ Chen CP | 2012 | Taiwan J Obstet Gyneeol2012，51，4： | 1 |
| 4 | Targeted agents in non-small celllung cancer therapy: What is there on the horizon显示文摘 | Villaflor VM Salgia R | 2013 | Car-cinog2013，12，： | 1 |
| 5 | Exosomes as a tumor vaccine:enhancing potency through direct loading of antigenic peptides显示文摘 | Hsu D H Paz P Villaflor G | 2003 | J Immunother2003，26，5： | 1 |
| 6 | Curcuminoids andresveratrol as anti-Alzheimer agents显示文摘 | Villaflores OB Chen YJ Chen CP | 2012 | Taiwanese journal ofobstetrics gynecology2012，51，4： | 1 |
| 7 | Single agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials显示文摘 | Lilenbaum R Villaflor V Langer C | 2009 | J Thorac Oncol2009，4，7： | 1 |
| 8 | Effects of curcumin and deme- thoxycnreumin on amyloid - β precursor and tau proteins through the in- ternal ribosome entry sites: A potential therapeutic for Alzheimer's dis- ease显示文摘 | Villaflores O B Chela Chen CP | 2012 | Taiwanese J Obst Gyneeol2012，51，4： | 1 |
| 9 | Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? 显示文摘 | Villaflor VM Salgia R | 2013 | J Carcinog2013，12，： | 1 |
| 10 | Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases显示文摘 | Lukas RV Nicholas MK Villaflor V | | 0，，01： | 1 |
| 11 | Effects of curcumin anddemethoxycurcumin on amyloid-p precursor and tau proteins throughthe internal ribosome entry sites: a potential therapeutic for Alzheimer ’ sdisease显示文摘 | Villaflores OB Chen YJ Chen GP | 2012 | Taiwan J Obstet Gynecol2012，51，4： | 1 |
| 12 | Targeted agents in non-small cell lung cancer therapy:what is there on the horizon显示文摘 | Villaflor VM Salgia R | | 0，，： | 1 |
| 13 | Temozolomide and/or erlotinib in the treatment of lung cancer patients with progressive central nervous system metastases显示文摘 | Lukas RV Nicholas MK Villaflor V | 2012 | J Neurol Res2012，2，1： | 1 |
| 14 | Exosomes as a tumor vaccine:enhancing potency through direct loading of antigenic peptides 显示文摘 | Hsu DH Paz P Villaflor G | 2003 | J Immunother2003，26，5： | 1 |
| 15 | Curcuminoids and res- veratrol as anti-Alzheimer agents 显示文摘 | Villaflores OB Chen YJ Chen CP | 2012 | Taiwan J Obstet Gynecol2012，51，4： | 1 |
| 16 | Curcuminoids and resveratroI as anti-Alzheimer agents显示文摘 | Villaflores OB Chen YJ Chen CP | 2012 | Taiwan J Obstet OinecoI2012，51，4： | 1 |
| 17 | Personalized Treatment of Lung Cancer显示文摘 | Ravi Salgia Thomas Hensing Nicholas Campbell April K. Salama Michael Maitland Philip Hoffman Victoria Villaflor Everett E. Vokes | 2011 | Seminars in Oncology2011，，2： | 1 |
| 18 | Exosomes as a tumor vaccine:enhancing potency through direct loading of antigenic peptides 显示文摘 | Paz P Villaflor G | 2003 | J Immunother2003，26，5： | 1 |
| 19 | Targeted agents in non-small cell lung cancer therapy: What is there on the horizon显示文摘 | Villaflor VM Salgia R | 2013 | Journal of car- cinogenesis2013，12，： | 1 |
| 20 | Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system显示文摘 | VILLAFLORES O B HSEI C M TENG C Y | 2013 | J Virol Metheds2013，189，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员